Treatment challenges for urogenital and anorectal Chlamydia trachomatis

Fabian Yuh Shiong Kong, Jane Simone Hocking, Fabian Yuh Shiong Kong, Jane Simone Hocking

Abstract

While true antimicrobial resistance to Chlamydia trachomatis is a rare occurrence, repeat chlamydia infections continue to be reported following treatment with a single 1 g dose of azithromycin or week long doxycycline - with considerable more concern about azithromycin treatment failure. While most repeat positive cases are likely to be reinfections, emerging evidence indicates treatment failure may play a role. Current data suggests that there may are differences in the efficacy of the drugs between rectal and non-rectal sites of infection and factors such as immune response, drug pharmacokinetics, organism load, auto-inoculation from rectum to cervix in women and the genital microbiome may play a role in treatment failure. Other possible reasons for repeat infection include the low discriminatory power of NAAT tests to differentiate between viable and nonviable organisms and failure to detect LGV infection. This review will present the current evidence regarding the management challenges for urogenital and anorectal chlamydia infections and provide some suggestions for where future research efforts are needed to address important knowledge gaps in this area and provide stronger evidence for the development of robust treatment guidelines.

References

    1. Wang SA, Papp JR, Stamm WE, Peeling RW, Martin DH, Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis: a meeting report. J Infect Dis. 2005;191(6):917–23. doi: 10.1086/428290.
    1. Horner P. The case for further treatment studies of uncomplicated genital Chlamydia trachomatis infection. Sex Transm Infect. 2006;82(4):340–3. doi: 10.1136/sti.2005.019158.
    1. Jordan SJ, Geisler WM. Azithromycin for rectal chlamydia: is it time to leave azithromycin on the shelf?…Not yet. Sex Transm Dis. 2014;41(2):86–8. doi: 10.1097/OLQ.0000000000000092.
    1. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75(1):3–17. doi: 10.1136/sti.75.1.3.
    1. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis. 2001;28(10):579–97. doi: 10.1097/00007435-200110000-00005.
    1. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):305–10. doi: 10.1097/COH.0b013e32833a8844.
    1. Aghaizu A, Reid F, Kerry S, Hay PE, Mallinson H, Jensen JS, et al. Frequency and risk factors for incident and redetected Chlamydia trachomatis infection in sexually active, young, multi-ethnic women: a community based cohort study. Sex Transm Infect. 2014;90(7):524–8. doi: 10.1136/sextrans-2014-051607.
    1. Walker J, Tabrizi SN, Fairley CK, Chen MY, Bradshaw CS, Twin J, et al. Chlamydia trachomatis incidence and re-Infection among young women – behavioural and microbiological characteristics. PLoS One. 2012;7(5) doi: 10.1371/journal.pone.0037778.
    1. LaMontagne D, Baster K, Emmett L, Nichols T, Randall S, McLean L, et al. Incidence and reinfection rates of genital chlamydia infection among women aged 16 to 24 years attending general practice, family planning and genitourinary medicine clinics in England: a prospective cohort study by the chlamydia recall study advisory group. Sex Transm Infect. 2007;83(4):292–303. doi: 10.1136/sti.2006.022053.
    1. Fung M, Scott KC, Kent CK, Klausner JD. Chlamydial and gonococcal reinfection among men: a systematic review of data to evaluate the need for retesting. Sex Transm Infect. 2007;83(4):304–9. doi: 10.1136/sti.2006.024059.
    1. Khosropour CM, Dombrowski JC, Barbee LA, Manhart LE, Golden MR. Comparing azithromycin and doxycycline for the treatment of rectal Chlamydial Infection: a retrospective cohort study. Sex Transm Dis. 2014;41(2):79–85. doi: 10.1097/OLQ.0000000000000088.
    1. Renault CA, Israelski DM, Levy V, Fujikawa BK, Kellogg TA, Klausner JD. Time to clearance of Chlamydia trachomatis ribosomal RNA in women treated for chlamydial infection. Sex Health. 2011;8(1):69–73. doi: 10.1071/SH10030.
    1. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2010. MMWR - Morb Mortal Wkly Rep. 2010;59(No.RR-12):1–116.
    1. Lanjouw E, Ossewaarde JM, Stary A, Boag F, van der Meijden WI. 2010 European guideline for the management of Chlamydia trachomatis infections. Int J STD AIDS. 2010;21(11):729–37. doi: 10.1258/ijsa.2010.010302.
    1. Australian STI management guidelines for use in primary care. []
    1. Lau C-Y, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis. 2002;29(9):497–502. doi: 10.1097/00007435-200209000-00001.
    1. Handsfield HH. Questioning azithromycin for chlamydial infection. Sex Transm Dis. 2011;38(11):1028–9. doi: 10.1097/OLQ.0b013e318227a366.
    1. Kong FYS, Tabrizi SN, Law M, Vodstrcil LA, Chen M, Fairley CK, et al. Azithromycin versus doxycycline for the treatment of genital chlamydia infection – a meta-analysis of randomised controlled trials. Clin Infect Dis. 2014;59(2):193–205. doi: 10.1093/cid/ciu220.
    1. Kong FYS, Tabrizi SN, Fairley CK, Vodstrcil LA, Huston WM, Chen M, et al. The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2015;70(5):1290–7. doi: 10.1093/jac/dku574.
    1. World Health Organization . Guidelines for the management of sexually transmitted infections. Geneva: WHO; 2003.
    1. Jones RB, Van Der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis. 1990;162(6):1309–15. doi: 10.1093/infdis/162.6.1309.
    1. Lefevre JC, Lepargneur JP. Comparative in vitro susceptibility of a tetracycline-resistant Chlamydia trachomatis strain isolated in Toulouse (France) Sex Transm Dis. 1998;25(7):350–2. doi: 10.1097/00007435-199808000-00005.
    1. Mourad A, Sweet RL, Sugg N, Schachter J. Relative resistance to erythromycin in Chlamydia trachomatis. Antimicrob Agents Chemother. 1980;18(5):696–8. doi: 10.1128/AAC.18.5.696.
    1. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000;181(4):1421–7. doi: 10.1086/315372.
    1. Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy. 2010;56(5):371–7. doi: 10.1159/000314998.
    1. Shkarupeta MM, Lazarev VN, Akopian TA, Afrikanova TS, Govorun VM. Analysis of antibiotic resistance markers in Chlamydia trachomatis clinical isolates obtained after ineffective antibiotic therapy. Bull Exp Biol Med. 2007;143(6):713–7. doi: 10.1007/s10517-007-0221-9.
    1. Zhu H, Wang HP, Jiang Y, Hou SP, Liu YJ, Liu QZ. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in Chlamydia trachomatis strains selected in vitro by macrolide passage. Andrologia. 2010;42(4):274–80. doi: 10.1111/j.1439-0272.2009.01019.x.
    1. Misyurina OY, Chipitsyna EV, Finashutina YP, Lazarev VN, Akopian TA, Savicheva AM, et al. Mutations in a 23S rRNA gene of Chlamydia trachomatis associated with resistance to macrolides. Antimicrob Agents Chemother. 2004;48(4):1347–9. doi: 10.1128/AAC.48.4.1347-1349.2004.
    1. Berger-Bächi B. Expression of resistance to methicillin. Trends Microbiol. 1994;2(10):389–93. doi: 10.1016/0966-842X(94)90617-3.
    1. Hogan RJ, Mathews SA, Mukhopadhyay S, Summersgill JT, Timms P. Chlamydial persistence: beyond the biphasic paradigm. Infect Immun. 2004;72(4):1843–55. doi: 10.1128/IAI.72.4.1843-1855.2004.
    1. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother. 2003;47(2):636–42. doi: 10.1128/AAC.47.2.636-642.2003.
    1. Vodstrcil LA, McIver R, Huston WM, Tabrizi SN, Timms P, Hocking JS. The epidemiology of organism load in genital Chlamydia trachomatis infection – a systematic review. J Infect Dis. 2015; 211 (10): 1628-1645.
    1. Kong FYS, Tabrizi S, Fairley CK, Phillips S, Huston W, Vodstrcil LA, et al. 18th International Union against Sexually Transmitted Infections (IUSTI) Asia-Pacific Conference, 11-14th November: 2014; Bangkok Thailand. 2014. Is repeat rectal chlamydia infection among men who have sex with men an issue?
    1. Horner PJ. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex Transm Infect. 2012;88(3):154–6. doi: 10.1136/sextrans-2011-050385.
    1. Phillips-Campbell R, Kintner J, Schoborg RV. Induction of the Chlamydia muridarum stress/persistence response increases Azithromycin-treatment failure in a murine model of infection. Antimicrob Agents Chemother. 2014;58(3):1782–4. doi: 10.1128/AAC.02097-13.
    1. Parnham MJ, Haber VE, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: Mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014;143(2):225–45. doi: 10.1016/j.pharmthera.2014.03.003.
    1. Rank RG, Yeruva L. “Hidden in plain sight:” Chlamydial gastrointestinal infection and its relevance to “persistence” in human genital infections. Infect Immun. 2014;82(4):1362–71. doi: 10.1128/IAI.01244-13.
    1. Heiligenberg M, Lutter R, Pajkrt D, Adams K, De Vries H, Heijman T, et al. Effect of HIV and chlamydia infection on rectal inflammation and cytokine concentrations in men who have sex with men. Clin Vaccine Immunol. 2013;20(10):1517–23. doi: 10.1128/CVI.00763-12.
    1. Kintner J, Lajoie D, Hall J, Whittimore J, Schoborg RV. Commonly prescribed β-lactam antibiotics induce C. trachomatis persistence/stress in culture at physiologically relevant concentrations. Front Cell Infect Microbiol. 2014;4:44. doi: 10.3389/fcimb.2014.00044.
    1. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis. 2010;201(Suppl 2):S88–95. doi: 10.1086/652394.
    1. Bragina EY, Gomberg MA, Dmitriev GA. Electron microscopic evidence of persistent chlamydial infection following treatment. J Eur Acad Dermatol Venereol. 2001;15(5):405–9. doi: 10.1046/j.1468-3083.2001.00342.x.
    1. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–50. doi: 10.1016/S1473-3099(14)70780-7.
    1. Patton M, Su J, Nelson R, Weinstock H. Primary and secondary syphilis--United States, 2005–2013. MMWR Morb Mortal Wkly Rep. 2014;63(18):402–6.
    1. Reveneau N, Crane DD, Fischer E, Caldwell HD. Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. Antimicrob Agents Chemother. 2005;49(5):1787–93. doi: 10.1128/AAC.49.5.1787-1793.2005.
    1. Vanover J, Sun J, Deka S, Kintner J, Duffourc MM, Schoborg RV. Herpes simplex virus co-infection-induced Chlamydia trachomatis persistence is not mediated by any known persistence inducer or anti-chlamydial pathway. Microbiology. 2008;154(3):971–8. doi: 10.1099/mic.0.2007/012161-0.
    1. Prusty BK, Böhme L, Bergmann B, Siegl C, Krause E, Mehlitz A, et al. Imbalanced oxidative stress causes chlamydial persistence during non-productive human herpes virus co-infection. PLoS One. 2012;7(10) doi: 10.1371/journal.pone.0047427.
    1. Vanover J, Kintner J, Whittimore J, Schoborg RV. Interaction of herpes simplex virus type 2 (HSV-2) glycoprotein D with the host cell surface is sufficient to induce Chlamydia trachomatis persistence. Microbiology. 2010;156(5):1294–302. doi: 10.1099/mic.0.036566-0.
    1. Deka S, Vanover J, Sun J, Kintner J, Whittimore J, Schoborg RV. An early event in the herpes simplex virus type-2 replication cycle is sufficient to induce Chlamydia trachomatis persistence. Cell Microbiol. 2007;9(3):725–37. doi: 10.1111/j.1462-5822.2006.00823.x.
    1. Broadbent A, McClure M, Ling A, Horner P. Chlamydia trachomatis do not enter a persistent state within human immunodeficiency virus type 1 (HIV-1) coinfected host cells, suggesting that HIV infection will not affect the efficacy of chlamydial antimicrobial therapy in vivo. HIV Med, 2010;(11):9
    1. Hocking J, Vodstrcil L, Huston W, Timms P, Chen M, Worthington K, et al. A cohort study of Chlamydia trachomatis treatment failure in women: a study protocol. BMC Infect Dis. 2013;13(1):379. doi: 10.1186/1471-2334-13-379.
    1. Caldwell HD, Wood H, Crane D, Bailey R, Jones RB, Mabey D, et al. Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest. 2003;111(11):1757–69. doi: 10.1172/JCI17993.
    1. Fehlner-Gardiner C, Roshick C, Carlson JH, Hughes S, Belland RJ, Caldwell HD, et al. Molecular basis defining human chlamydia trachomatis tissue tropism: A possible role for tryptophan synthase. J Biol Chem. 2002;277(30):26893–903. doi: 10.1074/jbc.M203937200.
    1. Unemo M, Ballard R, Ison C, Lewis D, Ndowa F, Peeling R. Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. 2013.
    1. Manavi K. A review on infection with Chlamydia trachomatis. Best Pract Res Cl Ob. 2006;20(6):941–51. doi: 10.1016/j.bpobgyn.2006.06.003.
    1. de Vrieze NHN, van Rooijen M, van der Loeff MF S, de Vries HJC. Anorectal and inguinal lymphogranuloma venereum among men who have sex with men in Amsterdam, The Netherlands: trends over time, symptomatology and concurrent infections. Sex Transm Infect. 2013;89(7):548–52. doi: 10.1136/sextrans-2012-050915.
    1. Haar K, Dudareva-Vizule S, Wisplinghoff H, Wisplinghoff F, Sailer A, Jansen K, et al. Lymphogranuloma venereum in men screened for pharyngeal and rectal infection, Germany. Emerg Infect Dis. 2013;19(3):488–92. doi: 10.3201/eid1903.121028.
    1. Annan N, Sullivan A, Nori A, Naydenova P, Alexander S, McKenna A, et al. Rectal chlamydia - a reservoir of undiagnosed infection in men who have sex with men. Sex Transm Infect. 2009;85:176–9. doi: 10.1136/sti.2008.031773.
    1. Barry PM, Kent CK, Philip SS, Klausner JD. Results of a program to test women for rectal chlamydia and gonorrhea. Obstet Gynecol. 2010;115(4):753–9. doi: 10.1097/AOG.0b013e3181d444f6.
    1. Hathorn E, Opie C, Goold P. What is the appropriate treatment for the management of rectal Chlamydia trachomatis in men and women? Sex Transm Infect. 2012;88(5):352–4. doi: 10.1136/sextrans-2011-050466.
    1. Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective study of perinatal transmission of chlamydia trachomatis. J Am Med Assoc. 1986;255(24):3374–7. doi: 10.1001/jama.1986.03370240044034.
    1. Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal) Lancet. 2013;382(9907):1781–94. doi: 10.1016/S0140-6736(13)62035-8.
    1. van Liere G, Hoebe C, Wolffs P, Dukers-Muijrers N. High co-occurrence of anorectal chlamydia with urogenital chlamydia in women visiting an STI clinic revealed by routine universal testing in an observational study; a recommendation towards a better anorectal chlamydia control in women. BMC Infect Dis. 2014;14(1):274. doi: 10.1186/1471-2334-14-274.
    1. Craig AP, Kong FYS, Yeruva L, Hocking JS, Rank RG, Wilson DP, et al. Is it time to switch to doxycycline from azithromycin for treating genital chlamydial infections? Modelling the impact of autoinoculation from the gastrointestinal tract to the genital tract. BMC Infect Dis. 2015;15:200. doi: 10.1186/s12879-015-0939-3.
    1. Khosropour CM, Manhart LE, Colombara DV, Gillespie CW, Lowens S, Totten PA, et al. Sub-optimal adherence to doxycycline and treatment outcomes among men with non-gonococcal urethritis: a prospective cohort study. Sex Transm Infect. 2014;90(1):3–7. doi: 10.1136/sextrans-2013-051174.
    1. Bachmann LH, Stephens J, Richey CM, Hook EW. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes - high therapeutic success rates despite poor compliance. Sex Transm Dis. 1999;26(5):272–8. doi: 10.1097/00007435-199905000-00006.
    1. Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun. 2002;70(6):2741–51. doi: 10.1128/IAI.70.6.2741-2751.2002.
    1. Su H, Morrison R, Messer R, Whitmire W, Hughes S, Caldwell HD. The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J Infect Dis. 1999;180(4):1252–8. doi: 10.1086/315046.
    1. Brunham RC, Rekart ML. The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis. 2008;35(1):53–4. doi: 10.1097/OLQ.0b013e31815e41a3.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere